Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Edgewise Therapeutics, Inc. Director's Dealing 2021

Mar 30, 2021

31829_dirs_2021-03-30_0215f145-a259-4618-a45c-624853089adf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edgewise Therapeutics, Inc. (EWTX)
CIK: 0001710072
Period of Report: 2021-03-30

Reporting Person: Flynn James E (10% Owner, Possible Member of 10% Group)
Reporting Person: Deerfield Mgmt IV, L.P. (10% Owner, Possible Member of 10% Group)
Reporting Person: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (10% Owner, Possible Member of 10% Group)
Reporting Person: Deerfield Private Design Fund IV, L.P. (10% Owner, Possible Member of 10% Group)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-03-30 Common Stock C 1572960 Acquired 1572960 Indirect
2021-03-30 Common Stock C 1301626 Acquired 2874586 Indirect
2021-03-30 Common Stock C 433551 Acquired 3308137 Indirect
2021-03-30 Common Stock P 625000 $16.00 Acquired 3933137 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-03-30 Series B-1 Preferred Stock $ C 1572960 Disposed Common Stock (1572960) Indirect
2021-03-30 Series B-2 Preferred Stock $ C 1301626 Disposed Common Stock (1301626) Indirect
2021-03-30 Series C Preferred Stock $ C 433551 Disposed Common Stock (433551) Indirect

Footnotes

F1: Each share of Series B-1 Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The number of shares reported herein gives effect to the 1-for-1.8932 reverse split of the Issuer's common stock effected by the Issuer on March 19, 2021 in connection with its initial public offering.

F2: This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (the "Fund"). Deerfield Management Company, L.P. is the investment manager of the Fund. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt IV, L.P. and Deerfield Management Company, L.P.

F3: In accordance with Instruction 4(b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Fund is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

F4: Each share of Series B-2 Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The number of shares reported herein gives effect to the 1-for-1.8932 reverse split of the Issuer's common stock effected by the Issuer on March 19, 2021 in connection with its initial public offering.

F5: Each share of Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering. The number of shares reported herein gives effect to the 1-for-1.8932 reverse split of the Issuer's common stock effected by the Issuer on March 19, 2021 in connection with its initial public offering.